Capital Analysts LLC’s Moderna MRNA Stock Holding History

Capital Analysts LLC’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$466K	Buy	9,179 +16	+0.2%	+$746	0.01%	466
2025 Q4	$270K	Sell	9,163 -15	-0.2%	-$408	0.01%	562
2025 Q3	$237K	Buy	9,178 +8,979	+4,512%	+$250K	0.01%	565
2025 Q2	$5K	Hold	199	–	–	﹤0.01%	1253
2025 Q1	$6K	Hold	199	–	–	﹤0.01%	1199
2024 Q4	$8K	Buy	199 +21	+12%	+$1K	﹤0.01%	1103
2024 Q3	$12K	Hold	178	–	–	﹤0.01%	1002
2024 Q2	$21K	Buy	178 +152	+585%	+$19.2K	﹤0.01%	851
2024 Q1	$3K	Hold	26	–	–	﹤0.01%	1028
2023 Q4	$3K	Hold	26	–	–	﹤0.01%	996
2023 Q3	$3K	Buy	26 +15	+136%	+$1.67K	﹤0.01%	1029
2023 Q2	$1K	Sell	11 -10	-48%	-$1.33K	﹤0.01%	978
2023 Q1	$3K	Buy	+21	New	+$3.46K	﹤0.01%	905
2021 Q4	–	Sell	-100	Closed	-$38K	–	1019
2021 Q3	$38K	Buy	+100	New	+$36.9K	﹤0.01%	617
2021 Q2	–	Sell	-200	Closed	-$26K	–	1042
2021 Q1	$26K	Buy	+200	New	+$29K	﹤0.01%	679

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Analysts LLC's MRNA Position: Q1 2026 in Review

Capital Analysts LLC increased its Moderna (MRNA) stake by 0.17% in Q1 2026, buying an estimated $746 and bringing the position to 9,179 shares worth $466K. The position accounts for 0.01% of the portfolio, ranked #466.

Capital Analysts LLC first reported a position in MRNA in Q1 2021 and has held it in 15 quarters since. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Capital Analysts LLC held 9,179 shares of Moderna worth $466K as of Q1 2026.
Capital Analysts LLC bought 16 Moderna shares in Q1 2026, an estimated $746.
Moderna made up 0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #466 holding.
Capital Analysts LLC first reported a position in Moderna in Q1 2021 and has held it in 15 quarters since.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.